Candriam SCA’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $20.8M | Buy |
260,327
+25,359
| +11% | +$2.09M | 0.11% | 187 |
|
|
2025
Q4 | $20M | Buy |
234,968
+172,978
| +279% | +$14.2M | 0.1% | 188 |
|
|
2025
Q3 | $4.82M | Buy |
61,990
+3,505
| +6% | +$274K | 0.03% | 378 |
|
|
2025
Q2 | $4.57M | Buy |
58,485
+1,838
| +3% | +$137K | 0.03% | 366 |
|
|
2025
Q1 | $4.11M | Sell |
56,647
-69,029
| -55% | -$4.94M | 0.03% | 370 |
|
|
2024
Q4 | $9.3M | Sell |
125,676
-1,559
| -1% | -$109K | 0.05% | 270 |
|
|
2024
Q3 | $8.4M | Sell |
127,235
-73,090
| -36% | -$5.31M | 0.05% | 291 |
|
|
2024
Q2 | $18.5M | Buy |
200,325
+150,662
| +303% | +$13.3M | 0.11% | 185 |
|
|
2024
Q1 | $4.75M | Buy |
49,663
+1,742
| +4% | +$146K | 0.03% | 353 |
|
|
2023
Q4 | $3.65M | Sell |
47,921
-70,824
| -60% | -$4.93M | 0.03% | 382 |
|
|
2023
Q3 | $8.23M | Sell |
118,745
-76,295
| -39% | -$6.13M | 0.06% | 251 |
|
|
2023
Q2 | $18.4M | Sell |
195,040
-68,754
| -26% | -$5.98M | 0.13% | 173 |
|
|
2023
Q1 | $20.1M | Sell |
263,794
-6,281
| -2% | -$494K | 0.14% | 167 |
|
|
2022
Q4 | $20.1M | Sell |
270,075
-220,201
| -45% | -$17M | 0.14% | 167 |
|
|
2022
Q3 | $40.5M | Buy |
490,276
+300,423
| +158% | +$28.9M | 0.29% | 80 |
|
|
2022
Q2 | $18.1M | Buy |
189,853
+14,035
| +8% | +$1.45M | 0.15% | 150 |
|
|
2022
Q1 | $20.7M | Buy |
175,818
+22,278
| +15% | +$2.5M | 0.14% | 159 |
|
|
2021
Q4 | $19.9M | Buy |
153,540
+38,591
| +34% | +$4.5M | 0.13% | 178 |
|
|
2021
Q3 | $13M | Buy |
114,949
+2,071
| +2% | +$236K | 0.09% | 232 |
|
|
2021
Q2 | $11.7M | Buy |
112,878
+16,688
| +17% | +$1.57M | 0.08% | 264 |
|
|
2021
Q1 | $8.43M | Hold |
96,190
| – | – | 0.07% | 280 |
|
|
2020
Q4 | $8.78M | Buy |
96,190
+8,927
| +10% | +$740K | 0.07% | 288 |
|
|
2020
Q3 | $6.96M | Sell |
87,263
-6,574
| -7% | -$513K | 0.07% | 296 |
|
|
2020
Q2 | $6.49M | Sell |
93,837
-4,005
| -4% | -$285K | 0.07% | 288 |
|
|
2020
Q1 | $7.44M | Hold |
97,842
| – | – | 0.08% | 269 |
|
|
2019
Q4 | $7.61M | Buy |
97,842
+5,835
| +6% | +$456K | 0.08% | 273 |
|
|
2019
Q3 | $6.74M | Buy |
92,007
+18,720
| +26% | +$1.32M | 0.09% | 263 |
|
|
2019
Q2 | $4.49M | Buy |
73,287
+2,478
| +3% | +$150K | 0.06% | 356 |
|
|
2019
Q1 | $4.52M | Hold |
70,809
| – | – | 0.06% | 350 |
|
|
2018
Q4 | $3.62M | Sell |
70,809
-3,009
| -4% | -$152K | 0.06% | 343 |
|
|
2018
Q3 | $4.28M | Sell |
73,818
-783
| -1% | -$38.3K | 0.06% | 351 |
|
|
2018
Q2 | $3.62M | Sell |
74,601
-33,711
| -31% | -$1.57M | 0.06% | 359 |
|
|
2018
Q1 | $5.04M | Buy |
108,312
+14,763
| +16% | +$641K | 0.09% | 281 |
|
|
2017
Q4 | $3.52M | Sell |
93,549
-972
| -1% | -$35.7K | 0.06% | 337 |
|
|
2017
Q3 | $3.44M | Buy |
94,521
+327
| +0.3% | +$12.5K | 0.06% | 347 |
|
|
2017
Q2 | $3.71M | Sell |
94,194
-14,028
| -13% | -$512K | 0.07% | 332 |
|
|
2017
Q1 | $3.39M | Buy |
108,222
+40,734
| +60% | +$1.28M | 0.07% | 339 |
|
|
2016
Q4 | $2.11M | Buy |
67,488
+8,769
| +15% | +$284K | 0.05% | 362 |
|
|
2016
Q3 | $2.36M | Sell |
58,719
-9,837
| -14% | -$370K | 0.06% | 327 |
|
|
2016
Q2 | $2.28M | Buy |
68,556
+3,870
| +6% | +$132K | 0.06% | 286 |
|
|
2016
Q1 | $1.89M | Buy |
+64,686
| New | +$1.78M | 0.05% | 331 |
|
|
2015
Q4 | – | Sell |
-16,398
| Closed | -$389K | – | 602 |
|
|
2015
Q3 | $389K | Sell |
16,398
-683,742
| -98% | -$16.5M | 0.01% | 557 |
|
|
2015
Q2 | $16.6M | Sell |
700,140
-121,968
| -15% | -$2.75M | 0.35% | 72 |
|
|
2015
Q1 | $19.5M | Sell |
822,108
-272,280
| -25% | -$6.11M | 0.39% | 63 |
|
|
2014
Q4 | $23.2M | Buy |
+1,094,388
| New | +$22M | 0.49% | 58 |
|
Other funds holding EW
VCM
VPM
Candriam SCA's EW Position: Q1 2026 in Review
Candriam SCA increased its Edwards Lifesciences (EW) stake by 11% in Q1 2026, buying an estimated $2.09M and bringing the position to 260,327 shares worth $20.8M. The position accounts for 0.11% of the portfolio, ranked #187.
Candriam SCA first reported a position in EW in Q4 2014 and has held it in 45 quarters since. The position peaked at $40.5M in Q3 2022. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Candriam SCA held 260,327 shares of Edwards Lifesciences worth $20.8M as of Q1 2026.
- Candriam SCA bought 25,359 Edwards Lifesciences shares in Q1 2026, an estimated $2.09M.
- Edwards Lifesciences made up 0.11% of Candriam SCA's portfolio in Q1 2026, its #187 holding.
- Candriam SCA first reported a position in Edwards Lifesciences in Q4 2014 and has held it in 45 quarters since.
- Candriam SCA's Edwards Lifesciences position peaked at $40.5M in Q3 2022.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Candriam SCA's 13F filing for Q1 2026, filed 30 Apr 2026.